Physician profile
Sunanda V Kane
NPI 1801957634
$22,515.93
in general payments reported to CMS, 2019-2025
12 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $5,240 · 2021: $4,600 · 2022: $5,225 · 2023: $3,310 · 2024: $2,715 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,010 · Food and Beverage: $315 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,010.00 |
| Food and Beverage | $315.28 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,415.28 | 2023-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $3,660.00 | 2022-2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,250.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,206.30 | 2019-2022 | |
| Gilead Sciences, INC. | $2,990.00 | 2020 | |
| Samsung Bioepis Co., Ltd. | $2,250.00 | 2020 | |
| Techlab, INC. | $1,200.00 | 2021 | |
| Biogen, INC. | $450.00 | 2021-2025 | Tysabri |
| Astrazeneca Pharmaceuticals Lp | $68.49 | 2025 | Imfinzi |
| Abbvie INC. | $14.43 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunanda Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.